Search Results : HIV

604 interactions found:

Novel Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
small nuclear ribonucleoprotein polypeptide A
Name2
muscleblind like splicing regulator 2
Pathway 1
  • mRNA Splicing - Major Pathway
Pathway 2
Drugs 1
  • Malonic acid
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Name 1
small nuclear ribonucleoprotein polypeptide A
Name2
poly(A) polymerase alpha
Pathway 1
  • mRNA Splicing - Major Pathway
Pathway 2
  • mRNA 3'-end processing
  • Processing of Capped Intron-Containing Pre-mRNA
  • RNA Polymerase II Transcription Termination
  • Processing of Intronless Pre-mRNAs
Drugs 1
  • Malonic acid
Drugs 2
  • Cordycepin Triphosphate
  • 3-sulfino-L-alanine
  • Triphosphoric acid
Diseases 1
Diseases 2
Novel
Novel
Name 1
PDZ domain containing 1
Name2
solute carrier family 17 member 1
Pathway 1
Pathway 2
  • Sodium-coupled phosphate cotransporters
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
FKBP prolyl isomerase 1A
Name2
ryanodine receptor 3
Pathway 1
  • mTORC1-mediated signalling
  • Calcineurin activates NFAT
  • Calcineurin activates NFAT
  • TGF-beta receptor signaling activates SMADs
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGFBR1 LBD Mutants in Cancer
  • Potential therapeutics for SARS
  • SARS-CoV-1 activates/modulates innate immune responses
Pathway 2
  • Stimuli-sensing channels
  • Ion homeostasis
Drugs 1
  • Pimecrolimus
  • Tacrolimus
  • (3R)-4-(p-toluenesulfonyl)-1,4-thiazane-3-carboxylicacid-L-phenylalanine ethyl ester
  • {3-[3-(3,4-Dimethoxy-Phenyl)-1-(1-{1-[2-(3,4,5-Trimethoxy-Phenyl)-Butyryl]-Piperidin-2yl}-Vinyloxy)-Propyl]-Phenoxy}-Acetic Acid
  • Gpi-1046
  • Methyl Methylsulfinylmethyl Sulfide
  • FKB-001
  • Heptyl glucoside
  • L-709,587
  • (3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Leucine
  • 4-hydroxybutan-2-one
  • GPI-1485
  • Myristic acid
  • (21S)-1AZA-4,4-DIMETHYL-6,19-DIOXA-2,3,7,20-TETRAOXOBICYCLO[19.4.0] PENTACOSANE
  • Dorsomorphin
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Name 1
amyloid beta precursor protein binding family B member 1
Name2
HIV-1 Tat specific factor 1
Pathway 1
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
Pathway 2
  • mRNA Splicing - Major Pathway
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
nuclear transcription factor Y subunit beta
Name2
TATA-box binding protein associated factor 12
Pathway 1
  • PPARA activates gene expression
  • Activation of gene expression by SREBF (SREBP)
  • Activation of gene expression by SREBF (SREBP)
  • ATF4 activates genes in response to endoplasmic reticulum stress
  • ATF6 (ATF6-alpha) activates chaperone genes
  • ATF6 (ATF6-alpha) activates chaperone genes
  • FOXO-mediated transcription of cell death genes
Pathway 2
  • HIV Transcription Initiation
  • RNA Polymerase II HIV Promoter Escape
  • Transcription of the HIV genome
  • HATs acetylate histones
  • RNA Polymerase II Pre-transcription Events
  • Regulation of TP53 Activity through Phosphorylation
  • RNA Polymerase II Promoter Escape
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
ABL proto-oncogene 1, non-receptor tyrosine kinase
Name2
roundabout guidance receptor 1
Pathway 1
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate WASPs and WAVEs
  • HDR through Single Strand Annealing (SSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Cyclin D associated events in G1
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX2 regulates osteoblast differentiation
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
Pathway 2
  • Netrin-1 signaling
  • Signaling by ROBO receptors
  • Signaling by ROBO receptors
  • Activation of RAC1
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • Inactivation of CDC42 and RAC1
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • SLIT2:ROBO1 increases RHOA activity
  • Regulation of cortical dendrite branching
  • Regulation of expression of SLITs and ROBOs
  • Regulation of expression of SLITs and ROBOs
Drugs 1
  • ATP
  • Imatinib
  • Dasatinib
  • N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
  • Nilotinib
  • XL228
  • Bosutinib
  • 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
  • Myristic acid
  • PD-166326
  • 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
  • 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
  • Regorafenib
  • Ponatinib
  • Fostamatinib
  • Brigatinib
  • Radotinib
  • Asciminib
  • Umbralisib
Drugs 2
Diseases 1
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
  • Chronic myeloid leukemia (CML)
Diseases 2
Novel
Novel
Symbols
Name 1
HRas proto-oncogene, GTPase
Name2
R-spondin 3
Pathway 1
  • SOS-mediated signalling
  • Activation of RAS in B cells
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Signalling to RAS
  • p38MAPK events
  • p38MAPK events
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • FCERI mediated MAPK activation
  • NCAM signaling for neurite out-growth
  • EPHB-mediated forward signaling
  • Ras activation upon Ca2+ influx through NMDA receptor
  • VEGFR2 mediated cell proliferation
  • CD209 (DC-SIGN) signaling
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • Regulation of RAS by GAPs
  • RAF activation
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • RAS signaling downstream of NF1 loss-of-function variants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Insulin receptor signalling cascade
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAS signaling
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Estrogen-stimulated signaling through PRKCZ
  • RAS processing
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by RAS GAP mutants
  • Signaling by RAS GTPase mutants
Pathway 2
  • Regulation of FZD by ubiquitination
  • RUNX1 regulates transcription of genes involved in WNT signaling
Drugs 1
  • Hexane-1,6-Diol
  • Trifluoroethanol
  • Guanosine-5'-Triphosphate
  • Guanosine-5'-Diphosphate
  • N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
  • Ursolic acid
Drugs 2
Diseases 1
  • Penile cancer
  • Cervical cancer
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Hepatocellular carcinoma
  • Thyroid cancer
  • Squamous cell carcinoma
  • Bladder cancer
Diseases 2
Novel
Novel
Symbols
Name 1
HRas proto-oncogene, GTPase
Name2
mitogen-activated protein kinase kinase 6
Pathway 1
  • SOS-mediated signalling
  • Activation of RAS in B cells
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Signalling to RAS
  • p38MAPK events
  • p38MAPK events
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • FCERI mediated MAPK activation
  • NCAM signaling for neurite out-growth
  • EPHB-mediated forward signaling
  • Ras activation upon Ca2+ influx through NMDA receptor
  • VEGFR2 mediated cell proliferation
  • CD209 (DC-SIGN) signaling
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • Regulation of RAS by GAPs
  • RAF activation
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • RAS signaling downstream of NF1 loss-of-function variants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Insulin receptor signalling cascade
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAS signaling
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Estrogen-stimulated signaling through PRKCZ
  • RAS processing
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by RAS GAP mutants
  • Signaling by RAS GTPase mutants
Pathway 2
  • NOD1/2 Signaling Pathway
  • Oxidative Stress Induced Senescence
  • activated TAK1 mediates p38 MAPK activation
  • Myogenesis
  • PI5P Regulates TP53 Acetylation
  • Interleukin-1 signaling
  • PKR-mediated signaling
Drugs 1
  • Hexane-1,6-Diol
  • Trifluoroethanol
  • Guanosine-5'-Triphosphate
  • Guanosine-5'-Diphosphate
  • N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
  • Ursolic acid
Drugs 2
  • Fostamatinib
  • Pimasertib
Diseases 1
  • Penile cancer
  • Cervical cancer
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Hepatocellular carcinoma
  • Thyroid cancer
  • Squamous cell carcinoma
  • Bladder cancer
Diseases 2
Novel
Novel
Symbols
Name 1
HRas proto-oncogene, GTPase
Name2
glutaminyl-peptide cyclotransferase
Pathway 1
  • SOS-mediated signalling
  • Activation of RAS in B cells
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Signalling to RAS
  • p38MAPK events
  • p38MAPK events
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • FCERI mediated MAPK activation
  • NCAM signaling for neurite out-growth
  • EPHB-mediated forward signaling
  • Ras activation upon Ca2+ influx through NMDA receptor
  • VEGFR2 mediated cell proliferation
  • CD209 (DC-SIGN) signaling
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • Regulation of RAS by GAPs
  • RAF activation
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • RAS signaling downstream of NF1 loss-of-function variants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Insulin receptor signalling cascade
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAS signaling
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Estrogen-stimulated signaling through PRKCZ
  • RAS processing
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by RAS GAP mutants
  • Signaling by RAS GTPase mutants
Pathway 2
  • Neutrophil degranulation
Drugs 1
  • Hexane-1,6-Diol
  • Trifluoroethanol
  • Guanosine-5'-Triphosphate
  • Guanosine-5'-Diphosphate
  • N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
  • Ursolic acid
Drugs 2
  • 1-benzylimidazole
  • N-acetylhistamine
  • Glutamine t-butyl ester
Diseases 1
  • Penile cancer
  • Cervical cancer
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Hepatocellular carcinoma
  • Thyroid cancer
  • Squamous cell carcinoma
  • Bladder cancer
Diseases 2
Novel
Novel
Name 1
transforming growth factor beta receptor 1
Name2
ring finger protein 130
Pathway 1
  • Downregulation of TGF-beta receptor signaling
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • UCH proteinases
  • Ub-specific processing proteases
  • TGFBR3 regulates TGF-beta signaling
Pathway 2
  • Antigen processing: Ubiquitination & Proteasome degradation
Drugs 1
  • 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline
  • Naphthyridine Inhibitor
  • 3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole
  • N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide
  • 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine
  • N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine
  • Fostamatinib
Drugs 2
Diseases 1
  • Loeys-Dietz syndrome (LDS)
  • Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)
Diseases 2
Novel
Novel
Name 1
transforming growth factor beta receptor 1
Name2
nucleoporin 37
Pathway 1
  • Downregulation of TGF-beta receptor signaling
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • UCH proteinases
  • Ub-specific processing proteases
  • TGFBR3 regulates TGF-beta signaling
Pathway 2
  • ISG15 antiviral mechanism
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Transport of the SLBP independent Mature mRNA
  • Transport of the SLBP Dependant Mature mRNA
  • Transport of Mature mRNA Derived from an Intronless Transcript
  • Transport of Mature mRNA derived from an Intron-Containing Transcript
  • Rev-mediated nuclear export of HIV RNA
  • Transport of Ribonucleoproteins into the Host Nucleus
  • NS1 Mediated Effects on Host Pathways
  • Viral Messenger RNA Synthesis
  • NEP/NS2 Interacts with the Cellular Export Machinery
  • Regulation of Glucokinase by Glucokinase Regulatory Protein
  • Nuclear import of Rev protein
  • Vpr-mediated nuclear import of PICs
  • IPs transport between nucleus and cytosol
  • IP3 and IP4 transport between cytosol and nucleus
  • IP6 and IP7 transport between cytosol and nucleus
  • snRNP Assembly
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • SUMOylation of DNA damage response and repair proteins
  • SUMOylation of ubiquitinylation proteins
  • Nuclear Pore Complex (NPC) Disassembly
  • Regulation of HSF1-mediated heat shock response
  • SUMOylation of SUMOylation proteins
  • SUMOylation of chromatin organization proteins
  • SUMOylation of RNA binding proteins
  • SUMOylation of DNA replication proteins
  • SUMOylation of DNA replication proteins
  • Transcriptional regulation by small RNAs
  • Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC)
  • RHO GTPases Activate Formins
  • tRNA processing in the nucleus
  • Mitotic Prometaphase
  • HCMV Early Events
  • HCMV Late Events
  • Postmitotic nuclear pore complex (NPC) reformation
  • Postmitotic nuclear pore complex (NPC) reformation
  • EML4 and NUDC in mitotic spindle formation
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
Drugs 1
  • 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline
  • Naphthyridine Inhibitor
  • 3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole
  • N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide
  • 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine
  • N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine
  • Fostamatinib
Drugs 2
Diseases 1
  • Loeys-Dietz syndrome (LDS)
  • Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)
Diseases 2
Novel
Novel
Name 1
TNF alpha induced protein 3
Name2
ring finger protein 168
Pathway 1
  • NOD1/2 Signaling Pathway
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • TNFR1-induced NF-kappa-B signaling pathway
  • Ovarian tumor domain proteases
  • Negative regulators of DDX58/IFIH1 signaling
Pathway 2
  • SUMOylation of DNA damage response and repair proteins
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Nonhomologous End-Joining (NHEJ)
  • Processing of DNA double-strand break ends
  • G2/M DNA damage checkpoint
Drugs 1
Drugs 2
Diseases 1
Diseases 2
  • RIDDLE syndrome
Novel
Novel
Symbols
Name 1
tumor protein p53
Name2
solute carrier family 9 member A9
Pathway 1
  • Activation of NOXA and translocation to mitochondria
  • Activation of PUMA and translocation to mitochondria
  • Pre-NOTCH Transcription and Translation
  • Oxidative Stress Induced Senescence
  • Formation of Senescence-Associated Heterochromatin Foci (SAHF)
  • Oncogene Induced Senescence
  • DNA Damage/Telomere Stress Induced Senescence
  • SUMOylation of transcription factors
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Association of TriC/CCT with target proteins during biosynthesis
  • Pyroptosis
  • TP53 Regulates Metabolic Genes
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Interleukin-4 and Interleukin-13 signaling
  • TP53 Regulates Transcription of DNA Repair Genes
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
  • TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
  • TP53 Regulates Transcription of Caspase Activators and Caspases
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Expression
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • Regulation of TP53 Activity through Methylation
  • PI5P Regulates TP53 Acetylation
  • G2/M DNA damage checkpoint
  • G2/M Checkpoints
  • Stabilization of p53
  • Transcriptional activation of cell cycle inhibitor p21
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • Transcriptional Regulation by VENTX
  • RUNX3 regulates CDKN1A transcription
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Loss of function of TP53 in cancer due to loss of tetramerization ability
  • Signaling by ALK fusions and activated point mutants
  • Regulation of NF-kappa B signaling
  • Zygotic genome activation (ZGA)
  • Factors involved in megakaryocyte development and platelet production
  • PKR-mediated signaling
Pathway 2
  • Sodium/Proton exchangers
  • Defective SLC9A9 causes autism 16 (AUTS16)
Drugs 1
  • Acetylsalicylic acid
  • Zinc
  • Triethyl phosphate
  • AZD 3355
  • 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
Drugs 2
Diseases 1
  • Chronic myeloid leukemia (CML)
  • Breast cancer
  • Non-small cell lung cancer
  • Gastric cancer
  • Adult T-cell leukemia
  • Choriocarcinoma
  • Esophageal cancer
  • Glioma
  • Pancreatic cancer
  • Vulvar cancer
  • Multiple myeloma
  • Choroid plexus papilloma
  • Ovarian cancer
  • Hepatocellular carcinoma
  • Squamous cell carcinoma
  • Endometrial Cancer
  • Penile cancer
  • Cancer of the anal canal
  • Hairy-cell leukemia
  • Oral cancer
  • Adrenal carcinoma
  • Malignant melanoma
  • Burkitt lymphoma
  • Thyroid cancer
  • Basal cell carcinoma
  • Small cell lung cancer
  • Gallbladder cancer
  • Bladder cancer
  • Laryngeal cancer
  • Kaposi's sarcoma
  • Cholangiocarcinoma
  • Chronic lymphocytic leukemia (CLL)
  • Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL)
  • Malignant pleural mesothelioma
  • Osteosarcoma
  • Colorectal cancer
Diseases 2
Novel
Novel
Symbols
Name 1
tumor protein p53
Name2
lysine demethylase 4C
Pathway 1
  • Activation of NOXA and translocation to mitochondria
  • Activation of PUMA and translocation to mitochondria
  • Pre-NOTCH Transcription and Translation
  • Oxidative Stress Induced Senescence
  • Formation of Senescence-Associated Heterochromatin Foci (SAHF)
  • Oncogene Induced Senescence
  • DNA Damage/Telomere Stress Induced Senescence
  • SUMOylation of transcription factors
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Association of TriC/CCT with target proteins during biosynthesis
  • Pyroptosis
  • TP53 Regulates Metabolic Genes
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Interleukin-4 and Interleukin-13 signaling
  • TP53 Regulates Transcription of DNA Repair Genes
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
  • TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
  • TP53 Regulates Transcription of Caspase Activators and Caspases
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Expression
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • Regulation of TP53 Activity through Methylation
  • PI5P Regulates TP53 Acetylation
  • G2/M DNA damage checkpoint
  • G2/M Checkpoints
  • Stabilization of p53
  • Transcriptional activation of cell cycle inhibitor p21
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • Transcriptional Regulation by VENTX
  • RUNX3 regulates CDKN1A transcription
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Loss of function of TP53 in cancer due to loss of tetramerization ability
  • Signaling by ALK fusions and activated point mutants
  • Regulation of NF-kappa B signaling
  • Zygotic genome activation (ZGA)
  • Factors involved in megakaryocyte development and platelet production
  • PKR-mediated signaling
Pathway 2
  • HDMs demethylate histones
  • Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
Drugs 1
  • Acetylsalicylic acid
  • Zinc
  • Triethyl phosphate
  • AZD 3355
  • 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
Drugs 2
Diseases 1
  • Chronic myeloid leukemia (CML)
  • Breast cancer
  • Non-small cell lung cancer
  • Gastric cancer
  • Adult T-cell leukemia
  • Choriocarcinoma
  • Esophageal cancer
  • Glioma
  • Pancreatic cancer
  • Vulvar cancer
  • Multiple myeloma
  • Choroid plexus papilloma
  • Ovarian cancer
  • Hepatocellular carcinoma
  • Squamous cell carcinoma
  • Endometrial Cancer
  • Penile cancer
  • Cancer of the anal canal
  • Hairy-cell leukemia
  • Oral cancer
  • Adrenal carcinoma
  • Malignant melanoma
  • Burkitt lymphoma
  • Thyroid cancer
  • Basal cell carcinoma
  • Small cell lung cancer
  • Gallbladder cancer
  • Bladder cancer
  • Laryngeal cancer
  • Kaposi's sarcoma
  • Cholangiocarcinoma
  • Chronic lymphocytic leukemia (CLL)
  • Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL)
  • Malignant pleural mesothelioma
  • Osteosarcoma
  • Colorectal cancer
Diseases 2
Novel
Novel
Name 1
proteasome 26S subunit ubiquitin receptor, non-ATPase 2
Name2
ubiquitin like domain containing CTD phosphatase 1
Pathway 1
  • Activation of NF-kappaB in B cells
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • ER-Phagosome pathway
  • Cross-presentation of soluble exogenous antigens (endosomes)
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • SCF-beta-TrCP mediated degradation of Emi1
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Vpu mediated degradation of CD4
  • Vif-mediated degradation of APOBEC3G
  • SCF(Skp2)-mediated degradation of p27/p21
  • Degradation of beta-catenin by the destruction complex
  • Downstream TCR signaling
  • Regulation of activated PAK-2p34 by proteasome mediated degradation
  • Separation of Sister Chromatids
  • FCERI mediated NF-kB activation
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Regulation of ornithine decarboxylase (ODC)
  • ABC-family proteins mediated transport
  • AUF1 (hnRNP D0) binds and destabilizes mRNA
  • Asymmetric localization of PCP proteins
  • Degradation of AXIN
  • Degradation of DVL
  • Hedgehog ligand biogenesis
  • Hh mutants are degraded by ERAD
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • Degradation of GLI1 by the proteasome
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Hedgehog 'on' state
  • Regulation of RAS by GAPs
  • TNFR2 non-canonical NF-kB pathway
  • NIK-->noncanonical NF-kB signaling
  • Defective CFTR causes cystic fibrosis
  • MAPK6/MAPK4 signaling
  • UCH proteinases
  • Ub-specific processing proteases
  • Neutrophil degranulation
  • Assembly of the pre-replicative complex
  • Orc1 removal from chromatin
  • CDK-mediated phosphorylation and removal of Cdc6
  • G2/M Checkpoints
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • Ubiquitin-dependent degradation of Cyclin D
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX3 expression and activity
  • Regulation of PTEN stability and activity
  • Neddylation
  • Regulation of expression of SLITs and ROBOs
  • Interleukin-1 signaling
  • Negative regulation of NOTCH4 signaling
  • KEAP1-NFE2L2 pathway
  • GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
  • Degradation of CDH1
  • Somitogenesis
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Proteasome assembly
  • Proteasome assembly
  • GSK3B-mediated proteasomal degradation of PD-L1(CD274)
  • SPOP-mediated proteasomal degradation of PD-L1(CD274)
  • AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)
  • Degradation of CRY and PER proteins
  • Degradation of CRY and PER proteins
  • Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide
  • Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
Name 1
kinase insert domain receptor
Name2
vascular endothelial growth factor C
Pathway 1
  • Neurophilin interactions with VEGF and VEGFR
  • VEGF binds to VEGFR leading to receptor dimerization
  • Integrin cell surface interactions
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated cell proliferation
  • Signaling by membrane-tethered fusions of PDGFRA or PDGFRB
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
Pathway 2
  • Platelet degranulation
  • VEGF ligand-receptor interactions
  • VEGF binds to VEGFR leading to receptor dimerization
Drugs 1
  • Sorafenib
  • Sunitinib
  • 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea
  • Cediranib
  • Vatalanib
  • XL999
  • TG-100801
  • XL820
  • CYC116
  • Ramucirumab
  • Pegdinetanib
  • RAF-265
  • Linifanib
  • IMC-1C11
  • Semaxanib
  • Pazopanib
  • Midostaurin
  • Axitinib
  • 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide
  • N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide
  • N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide
  • 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide
  • N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE
  • N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE
  • 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one
  • 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one
  • N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide
  • N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
  • N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
  • Cabozantinib
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Tivozanib
  • Fostamatinib
  • Erdafitinib
  • Foretinib
  • Ripretinib
  • Pralsetinib
  • Olinvacimab
Drugs 2
Diseases 1
Diseases 2
  • Gastric cancer
Novel
Novel
Name 1
SMAD family member 4
Name2
nucleoporin 214
Pathway 1
  • Signaling by NODAL
  • Signaling by NODAL
  • Signaling by Activin
  • Signaling by Activin
  • Signaling by BMP
  • TGF-beta receptor signaling activates SMADs
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • SMAD4 MH2 Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Transcriptional regulation of pluripotent stem cells
  • Ub-specific processing proteases
  • RUNX2 regulates bone development
  • RUNX3 regulates CDKN1A transcription
  • RUNX3 regulates BCL2L11 (BIM) transcription
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of cell cycle genes
  • FOXO-mediated transcription of cell cycle genes
  • Cardiogenesis
  • SARS-CoV-1 targets host intracellular signalling and regulatory pathways
  • Germ layer formation at gastrulation
  • Formation of definitive endoderm
  • Formation of definitive endoderm
  • TGFBR3 expression
  • Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
Pathway 2
  • ISG15 antiviral mechanism
  • Transport of the SLBP independent Mature mRNA
  • Transport of the SLBP Dependant Mature mRNA
  • Transport of Mature mRNA Derived from an Intronless Transcript
  • Transport of Mature mRNA derived from an Intron-Containing Transcript
  • Rev-mediated nuclear export of HIV RNA
  • Transport of Ribonucleoproteins into the Host Nucleus
  • NS1 Mediated Effects on Host Pathways
  • Viral Messenger RNA Synthesis
  • NEP/NS2 Interacts with the Cellular Export Machinery
  • Regulation of Glucokinase by Glucokinase Regulatory Protein
  • Nuclear import of Rev protein
  • Vpr-mediated nuclear import of PICs
  • IPs transport between nucleus and cytosol
  • IP3 and IP4 transport between cytosol and nucleus
  • IP6 and IP7 transport between cytosol and nucleus
  • snRNP Assembly
  • SUMOylation of DNA damage response and repair proteins
  • SUMOylation of ubiquitinylation proteins
  • Nuclear Pore Complex (NPC) Disassembly
  • Regulation of HSF1-mediated heat shock response
  • SUMOylation of SUMOylation proteins
  • HuR (ELAVL1) binds and stabilizes mRNA
  • SUMOylation of chromatin organization proteins
  • SUMOylation of RNA binding proteins
  • SUMOylation of DNA replication proteins
  • SUMOylation of DNA replication proteins
  • Transcriptional regulation by small RNAs
  • Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC)
  • tRNA processing in the nucleus
  • HCMV Early Events
  • HCMV Late Events
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
Drugs 1
Drugs 2
Diseases 1
  • Colorectal cancer
  • Juvenile polyposis syndrome
  • Hereditary hemorrhagic telangiectasia (HHT)
  • Pancreatic cancer
Diseases 2
Novel
Novel
Name 1
SMAD family member 4
Name2
notch receptor 4
Pathway 1
  • Signaling by NODAL
  • Signaling by NODAL
  • Signaling by Activin
  • Signaling by Activin
  • Signaling by BMP
  • TGF-beta receptor signaling activates SMADs
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • SMAD4 MH2 Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Transcriptional regulation of pluripotent stem cells
  • Ub-specific processing proteases
  • RUNX2 regulates bone development
  • RUNX3 regulates CDKN1A transcription
  • RUNX3 regulates BCL2L11 (BIM) transcription
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of cell cycle genes
  • FOXO-mediated transcription of cell cycle genes
  • Cardiogenesis
  • SARS-CoV-1 targets host intracellular signalling and regulatory pathways
  • Germ layer formation at gastrulation
  • Formation of definitive endoderm
  • Formation of definitive endoderm
  • TGFBR3 expression
  • Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
Pathway 2
  • Pre-NOTCH Processing in the Endoplasmic Reticulum
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Processing in Golgi
  • Pre-NOTCH Processing in Golgi
  • Notch-HLH transcription pathway
  • Defective LFNG causes SCDO3
  • NOTCH4 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • Negative regulation of NOTCH4 signaling
  • Negative regulation of NOTCH4 signaling
Drugs 1
Drugs 2
Diseases 1
  • Colorectal cancer
  • Juvenile polyposis syndrome
  • Hereditary hemorrhagic telangiectasia (HHT)
  • Pancreatic cancer
Diseases 2
Novel
Novel
Symbols
Name 1
actinin alpha 3
Name2
calcium dependent secretion activator
Pathway 1
  • Nephrin family interactions
  • Striated Muscle Contraction
Pathway 2
Drugs 1
Drugs 2
  • Calcium citrate
  • Calcium Phosphate
  • Calcium phosphate dihydrate
Diseases 1
Diseases 2
Novel
Symbols
Name 1
small nuclear ribonucleoprotein polypeptide A
Name2
muscleblind like splicing regulator 2
Pathway 1
  • mRNA Splicing - Major Pathway
Pathway 2
Drugs 1
  • Malonic acid
Drugs 2
Diseases 1
Diseases 2
Novel
Name 1
small nuclear ribonucleoprotein polypeptide A
Name2
poly(A) polymerase alpha
Pathway 1
  • mRNA Splicing - Major Pathway
Pathway 2
  • mRNA 3'-end processing
  • Processing of Capped Intron-Containing Pre-mRNA
  • RNA Polymerase II Transcription Termination
  • Processing of Intronless Pre-mRNAs
Drugs 1
  • Malonic acid
Drugs 2
  • Cordycepin Triphosphate
  • 3-sulfino-L-alanine
  • Triphosphoric acid
Diseases 1
Diseases 2
Novel
Name 1
PDZ domain containing 1
Name2
solute carrier family 17 member 1
Pathway 1
Pathway 2
  • Sodium-coupled phosphate cotransporters
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
Name 1
FKBP prolyl isomerase 1A
Name2
ryanodine receptor 3
Pathway 1
  • mTORC1-mediated signalling
  • Calcineurin activates NFAT
  • Calcineurin activates NFAT
  • TGF-beta receptor signaling activates SMADs
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGFBR1 LBD Mutants in Cancer
  • Potential therapeutics for SARS
  • SARS-CoV-1 activates/modulates innate immune responses
Pathway 2
  • Stimuli-sensing channels
  • Ion homeostasis
Drugs 1
  • Pimecrolimus
  • Tacrolimus
  • (3R)-4-(p-toluenesulfonyl)-1,4-thiazane-3-carboxylicacid-L-phenylalanine ethyl ester
  • {3-[3-(3,4-Dimethoxy-Phenyl)-1-(1-{1-[2-(3,4,5-Trimethoxy-Phenyl)-Butyryl]-Piperidin-2yl}-Vinyloxy)-Propyl]-Phenoxy}-Acetic Acid
  • Gpi-1046
  • Methyl Methylsulfinylmethyl Sulfide
  • FKB-001
  • Heptyl glucoside
  • L-709,587
  • (3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Leucine
  • 4-hydroxybutan-2-one
  • GPI-1485
  • Myristic acid
  • (21S)-1AZA-4,4-DIMETHYL-6,19-DIOXA-2,3,7,20-TETRAOXOBICYCLO[19.4.0] PENTACOSANE
  • Dorsomorphin
Drugs 2
Diseases 1
Diseases 2
Novel
Name 1
amyloid beta precursor protein binding family B member 1
Name2
HIV-1 Tat specific factor 1
Pathway 1
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
Pathway 2
  • mRNA Splicing - Major Pathway
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
Name 1
nuclear transcription factor Y subunit beta
Name2
TATA-box binding protein associated factor 12
Pathway 1
  • PPARA activates gene expression
  • Activation of gene expression by SREBF (SREBP)
  • Activation of gene expression by SREBF (SREBP)
  • ATF4 activates genes in response to endoplasmic reticulum stress
  • ATF6 (ATF6-alpha) activates chaperone genes
  • ATF6 (ATF6-alpha) activates chaperone genes
  • FOXO-mediated transcription of cell death genes
Pathway 2
  • HIV Transcription Initiation
  • RNA Polymerase II HIV Promoter Escape
  • Transcription of the HIV genome
  • HATs acetylate histones
  • RNA Polymerase II Pre-transcription Events
  • Regulation of TP53 Activity through Phosphorylation
  • RNA Polymerase II Promoter Escape
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
Name 1
ABL proto-oncogene 1, non-receptor tyrosine kinase
Name2
roundabout guidance receptor 1
Pathway 1
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate WASPs and WAVEs
  • HDR through Single Strand Annealing (SSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Cyclin D associated events in G1
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX2 regulates osteoblast differentiation
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
Pathway 2
  • Netrin-1 signaling
  • Signaling by ROBO receptors
  • Signaling by ROBO receptors
  • Activation of RAC1
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • Inactivation of CDC42 and RAC1
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • SLIT2:ROBO1 increases RHOA activity
  • Regulation of cortical dendrite branching
  • Regulation of expression of SLITs and ROBOs
  • Regulation of expression of SLITs and ROBOs
Drugs 1
  • ATP
  • Imatinib
  • Dasatinib
  • N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
  • Nilotinib
  • XL228
  • Bosutinib
  • 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
  • Myristic acid
  • PD-166326
  • 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
  • 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
  • Regorafenib
  • Ponatinib
  • Fostamatinib
  • Brigatinib
  • Radotinib
  • Asciminib
  • Umbralisib
Drugs 2
Diseases 1
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
  • Chronic myeloid leukemia (CML)
Diseases 2
Novel
Symbols
Name 1
HRas proto-oncogene, GTPase
Name2
R-spondin 3
Pathway 1
  • SOS-mediated signalling
  • Activation of RAS in B cells
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Signalling to RAS
  • p38MAPK events
  • p38MAPK events
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • FCERI mediated MAPK activation
  • NCAM signaling for neurite out-growth
  • EPHB-mediated forward signaling
  • Ras activation upon Ca2+ influx through NMDA receptor
  • VEGFR2 mediated cell proliferation
  • CD209 (DC-SIGN) signaling
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • Regulation of RAS by GAPs
  • RAF activation
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • RAS signaling downstream of NF1 loss-of-function variants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Insulin receptor signalling cascade
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAS signaling
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Estrogen-stimulated signaling through PRKCZ
  • RAS processing
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by RAS GAP mutants
  • Signaling by RAS GTPase mutants
Pathway 2
  • Regulation of FZD by ubiquitination
  • RUNX1 regulates transcription of genes involved in WNT signaling
Drugs 1
  • Hexane-1,6-Diol
  • Trifluoroethanol
  • Guanosine-5'-Triphosphate
  • Guanosine-5'-Diphosphate
  • N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
  • Ursolic acid
Drugs 2
Diseases 1
  • Penile cancer
  • Cervical cancer
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Hepatocellular carcinoma
  • Thyroid cancer
  • Squamous cell carcinoma
  • Bladder cancer
Diseases 2
Novel
Symbols
Name 1
HRas proto-oncogene, GTPase
Name2
mitogen-activated protein kinase kinase 6
Pathway 1
  • SOS-mediated signalling
  • Activation of RAS in B cells
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Signalling to RAS
  • p38MAPK events
  • p38MAPK events
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • FCERI mediated MAPK activation
  • NCAM signaling for neurite out-growth
  • EPHB-mediated forward signaling
  • Ras activation upon Ca2+ influx through NMDA receptor
  • VEGFR2 mediated cell proliferation
  • CD209 (DC-SIGN) signaling
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • Regulation of RAS by GAPs
  • RAF activation
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • RAS signaling downstream of NF1 loss-of-function variants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Insulin receptor signalling cascade
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAS signaling
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Estrogen-stimulated signaling through PRKCZ
  • RAS processing
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by RAS GAP mutants
  • Signaling by RAS GTPase mutants
Pathway 2
  • NOD1/2 Signaling Pathway
  • Oxidative Stress Induced Senescence
  • activated TAK1 mediates p38 MAPK activation
  • Myogenesis
  • PI5P Regulates TP53 Acetylation
  • Interleukin-1 signaling
  • PKR-mediated signaling
Drugs 1
  • Hexane-1,6-Diol
  • Trifluoroethanol
  • Guanosine-5'-Triphosphate
  • Guanosine-5'-Diphosphate
  • N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
  • Ursolic acid
Drugs 2
  • Fostamatinib
  • Pimasertib
Diseases 1
  • Penile cancer
  • Cervical cancer
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Hepatocellular carcinoma
  • Thyroid cancer
  • Squamous cell carcinoma
  • Bladder cancer
Diseases 2
Novel
Symbols
Name 1
HRas proto-oncogene, GTPase
Name2
glutaminyl-peptide cyclotransferase
Pathway 1
  • SOS-mediated signalling
  • Activation of RAS in B cells
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Signalling to RAS
  • p38MAPK events
  • p38MAPK events
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • FCERI mediated MAPK activation
  • NCAM signaling for neurite out-growth
  • EPHB-mediated forward signaling
  • Ras activation upon Ca2+ influx through NMDA receptor
  • VEGFR2 mediated cell proliferation
  • CD209 (DC-SIGN) signaling
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • Regulation of RAS by GAPs
  • RAF activation
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • RAS signaling downstream of NF1 loss-of-function variants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Insulin receptor signalling cascade
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAS signaling
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Estrogen-stimulated signaling through PRKCZ
  • RAS processing
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by RAS GAP mutants
  • Signaling by RAS GTPase mutants
Pathway 2
  • Neutrophil degranulation
Drugs 1
  • Hexane-1,6-Diol
  • Trifluoroethanol
  • Guanosine-5'-Triphosphate
  • Guanosine-5'-Diphosphate
  • N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
  • Ursolic acid
Drugs 2
  • 1-benzylimidazole
  • N-acetylhistamine
  • Glutamine t-butyl ester
Diseases 1
  • Penile cancer
  • Cervical cancer
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Hepatocellular carcinoma
  • Thyroid cancer
  • Squamous cell carcinoma
  • Bladder cancer
Diseases 2
Novel
Name 1
transforming growth factor beta receptor 1
Name2
ring finger protein 130
Pathway 1
  • Downregulation of TGF-beta receptor signaling
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • UCH proteinases
  • Ub-specific processing proteases
  • TGFBR3 regulates TGF-beta signaling
Pathway 2
  • Antigen processing: Ubiquitination & Proteasome degradation
Drugs 1
  • 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline
  • Naphthyridine Inhibitor
  • 3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole
  • N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide
  • 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine
  • N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine
  • Fostamatinib
Drugs 2
Diseases 1
  • Loeys-Dietz syndrome (LDS)
  • Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)
Diseases 2
Novel
Name 1
transforming growth factor beta receptor 1
Name2
nucleoporin 37
Pathway 1
  • Downregulation of TGF-beta receptor signaling
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • UCH proteinases
  • Ub-specific processing proteases
  • TGFBR3 regulates TGF-beta signaling
Pathway 2
  • ISG15 antiviral mechanism
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Transport of the SLBP independent Mature mRNA
  • Transport of the SLBP Dependant Mature mRNA
  • Transport of Mature mRNA Derived from an Intronless Transcript
  • Transport of Mature mRNA derived from an Intron-Containing Transcript
  • Rev-mediated nuclear export of HIV RNA
  • Transport of Ribonucleoproteins into the Host Nucleus
  • NS1 Mediated Effects on Host Pathways
  • Viral Messenger RNA Synthesis
  • NEP/NS2 Interacts with the Cellular Export Machinery
  • Regulation of Glucokinase by Glucokinase Regulatory Protein
  • Nuclear import of Rev protein
  • Vpr-mediated nuclear import of PICs
  • IPs transport between nucleus and cytosol
  • IP3 and IP4 transport between cytosol and nucleus
  • IP6 and IP7 transport between cytosol and nucleus
  • snRNP Assembly
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • SUMOylation of DNA damage response and repair proteins
  • SUMOylation of ubiquitinylation proteins
  • Nuclear Pore Complex (NPC) Disassembly
  • Regulation of HSF1-mediated heat shock response
  • SUMOylation of SUMOylation proteins
  • SUMOylation of chromatin organization proteins
  • SUMOylation of RNA binding proteins
  • SUMOylation of DNA replication proteins
  • SUMOylation of DNA replication proteins
  • Transcriptional regulation by small RNAs
  • Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC)
  • RHO GTPases Activate Formins
  • tRNA processing in the nucleus
  • Mitotic Prometaphase
  • HCMV Early Events
  • HCMV Late Events
  • Postmitotic nuclear pore complex (NPC) reformation
  • Postmitotic nuclear pore complex (NPC) reformation
  • EML4 and NUDC in mitotic spindle formation
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
Drugs 1
  • 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline
  • Naphthyridine Inhibitor
  • 3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole
  • N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide
  • 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine
  • N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine
  • Fostamatinib
Drugs 2
Diseases 1
  • Loeys-Dietz syndrome (LDS)
  • Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)
Diseases 2
Novel
Name 1
TNF alpha induced protein 3
Name2
ring finger protein 168
Pathway 1
  • NOD1/2 Signaling Pathway
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • TNFR1-induced NF-kappa-B signaling pathway
  • Ovarian tumor domain proteases
  • Negative regulators of DDX58/IFIH1 signaling
Pathway 2
  • SUMOylation of DNA damage response and repair proteins
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Nonhomologous End-Joining (NHEJ)
  • Processing of DNA double-strand break ends
  • G2/M DNA damage checkpoint
Drugs 1
Drugs 2
Diseases 1
Diseases 2
  • RIDDLE syndrome
Novel
Symbols
Name 1
tumor protein p53
Name2
solute carrier family 9 member A9
Pathway 1
  • Activation of NOXA and translocation to mitochondria
  • Activation of PUMA and translocation to mitochondria
  • Pre-NOTCH Transcription and Translation
  • Oxidative Stress Induced Senescence
  • Formation of Senescence-Associated Heterochromatin Foci (SAHF)
  • Oncogene Induced Senescence
  • DNA Damage/Telomere Stress Induced Senescence
  • SUMOylation of transcription factors
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Association of TriC/CCT with target proteins during biosynthesis
  • Pyroptosis
  • TP53 Regulates Metabolic Genes
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Interleukin-4 and Interleukin-13 signaling
  • TP53 Regulates Transcription of DNA Repair Genes
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
  • TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
  • TP53 Regulates Transcription of Caspase Activators and Caspases
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Expression
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • Regulation of TP53 Activity through Methylation
  • PI5P Regulates TP53 Acetylation
  • G2/M DNA damage checkpoint
  • G2/M Checkpoints
  • Stabilization of p53
  • Transcriptional activation of cell cycle inhibitor p21
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • Transcriptional Regulation by VENTX
  • RUNX3 regulates CDKN1A transcription
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Loss of function of TP53 in cancer due to loss of tetramerization ability
  • Signaling by ALK fusions and activated point mutants
  • Regulation of NF-kappa B signaling
  • Zygotic genome activation (ZGA)
  • Factors involved in megakaryocyte development and platelet production
  • PKR-mediated signaling
Pathway 2
  • Sodium/Proton exchangers
  • Defective SLC9A9 causes autism 16 (AUTS16)
Drugs 1
  • Acetylsalicylic acid
  • Zinc
  • Triethyl phosphate
  • AZD 3355
  • 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
Drugs 2
Diseases 1
  • Chronic myeloid leukemia (CML)
  • Breast cancer
  • Non-small cell lung cancer
  • Gastric cancer
  • Adult T-cell leukemia
  • Choriocarcinoma
  • Esophageal cancer
  • Glioma
  • Pancreatic cancer
  • Vulvar cancer
  • Multiple myeloma
  • Choroid plexus papilloma
  • Ovarian cancer
  • Hepatocellular carcinoma
  • Squamous cell carcinoma
  • Endometrial Cancer
  • Penile cancer
  • Cancer of the anal canal
  • Hairy-cell leukemia
  • Oral cancer
  • Adrenal carcinoma
  • Malignant melanoma
  • Burkitt lymphoma
  • Thyroid cancer
  • Basal cell carcinoma
  • Small cell lung cancer
  • Gallbladder cancer
  • Bladder cancer
  • Laryngeal cancer
  • Kaposi's sarcoma
  • Cholangiocarcinoma
  • Chronic lymphocytic leukemia (CLL)
  • Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL)
  • Malignant pleural mesothelioma
  • Osteosarcoma
  • Colorectal cancer
Diseases 2
Novel
Symbols
Name 1
tumor protein p53
Name2
lysine demethylase 4C
Pathway 1
  • Activation of NOXA and translocation to mitochondria
  • Activation of PUMA and translocation to mitochondria
  • Pre-NOTCH Transcription and Translation
  • Oxidative Stress Induced Senescence
  • Formation of Senescence-Associated Heterochromatin Foci (SAHF)
  • Oncogene Induced Senescence
  • DNA Damage/Telomere Stress Induced Senescence
  • SUMOylation of transcription factors
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Association of TriC/CCT with target proteins during biosynthesis
  • Pyroptosis
  • TP53 Regulates Metabolic Genes
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Interleukin-4 and Interleukin-13 signaling
  • TP53 Regulates Transcription of DNA Repair Genes
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
  • TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
  • TP53 Regulates Transcription of Caspase Activators and Caspases
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Expression
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • Regulation of TP53 Activity through Methylation
  • PI5P Regulates TP53 Acetylation
  • G2/M DNA damage checkpoint
  • G2/M Checkpoints
  • Stabilization of p53
  • Transcriptional activation of cell cycle inhibitor p21
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • Transcriptional Regulation by VENTX
  • RUNX3 regulates CDKN1A transcription
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Loss of function of TP53 in cancer due to loss of tetramerization ability
  • Signaling by ALK fusions and activated point mutants
  • Regulation of NF-kappa B signaling
  • Zygotic genome activation (ZGA)
  • Factors involved in megakaryocyte development and platelet production
  • PKR-mediated signaling
Pathway 2
  • HDMs demethylate histones
  • Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
Drugs 1
  • Acetylsalicylic acid
  • Zinc
  • Triethyl phosphate
  • AZD 3355
  • 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
Drugs 2
Diseases 1
  • Chronic myeloid leukemia (CML)
  • Breast cancer
  • Non-small cell lung cancer
  • Gastric cancer
  • Adult T-cell leukemia
  • Choriocarcinoma
  • Esophageal cancer
  • Glioma
  • Pancreatic cancer
  • Vulvar cancer
  • Multiple myeloma
  • Choroid plexus papilloma
  • Ovarian cancer
  • Hepatocellular carcinoma
  • Squamous cell carcinoma
  • Endometrial Cancer
  • Penile cancer
  • Cancer of the anal canal
  • Hairy-cell leukemia
  • Oral cancer
  • Adrenal carcinoma
  • Malignant melanoma
  • Burkitt lymphoma
  • Thyroid cancer
  • Basal cell carcinoma
  • Small cell lung cancer
  • Gallbladder cancer
  • Bladder cancer
  • Laryngeal cancer
  • Kaposi's sarcoma
  • Cholangiocarcinoma
  • Chronic lymphocytic leukemia (CLL)
  • Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL)
  • Malignant pleural mesothelioma
  • Osteosarcoma
  • Colorectal cancer
Diseases 2
Novel
Name 1
proteasome 26S subunit ubiquitin receptor, non-ATPase 2
Name2
ubiquitin like domain containing CTD phosphatase 1
Pathway 1
  • Activation of NF-kappaB in B cells
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • ER-Phagosome pathway
  • Cross-presentation of soluble exogenous antigens (endosomes)
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • SCF-beta-TrCP mediated degradation of Emi1
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Vpu mediated degradation of CD4
  • Vif-mediated degradation of APOBEC3G
  • SCF(Skp2)-mediated degradation of p27/p21
  • Degradation of beta-catenin by the destruction complex
  • Downstream TCR signaling
  • Regulation of activated PAK-2p34 by proteasome mediated degradation
  • Separation of Sister Chromatids
  • FCERI mediated NF-kB activation
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Regulation of ornithine decarboxylase (ODC)
  • ABC-family proteins mediated transport
  • AUF1 (hnRNP D0) binds and destabilizes mRNA
  • Asymmetric localization of PCP proteins
  • Degradation of AXIN
  • Degradation of DVL
  • Hedgehog ligand biogenesis
  • Hh mutants are degraded by ERAD
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • Degradation of GLI1 by the proteasome
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Hedgehog 'on' state
  • Regulation of RAS by GAPs
  • TNFR2 non-canonical NF-kB pathway
  • NIK-->noncanonical NF-kB signaling
  • Defective CFTR causes cystic fibrosis
  • MAPK6/MAPK4 signaling
  • UCH proteinases
  • Ub-specific processing proteases
  • Neutrophil degranulation
  • Assembly of the pre-replicative complex
  • Orc1 removal from chromatin
  • CDK-mediated phosphorylation and removal of Cdc6
  • G2/M Checkpoints
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • Ubiquitin-dependent degradation of Cyclin D
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX3 expression and activity
  • Regulation of PTEN stability and activity
  • Neddylation
  • Regulation of expression of SLITs and ROBOs
  • Interleukin-1 signaling
  • Negative regulation of NOTCH4 signaling
  • KEAP1-NFE2L2 pathway
  • GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
  • Degradation of CDH1
  • Somitogenesis
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Proteasome assembly
  • Proteasome assembly
  • GSK3B-mediated proteasomal degradation of PD-L1(CD274)
  • SPOP-mediated proteasomal degradation of PD-L1(CD274)
  • AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)
  • Degradation of CRY and PER proteins
  • Degradation of CRY and PER proteins
  • Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide
  • Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
Name 1
kinase insert domain receptor
Name2
vascular endothelial growth factor C
Pathway 1
  • Neurophilin interactions with VEGF and VEGFR
  • VEGF binds to VEGFR leading to receptor dimerization
  • Integrin cell surface interactions
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated cell proliferation
  • Signaling by membrane-tethered fusions of PDGFRA or PDGFRB
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
Pathway 2
  • Platelet degranulation
  • VEGF ligand-receptor interactions
  • VEGF binds to VEGFR leading to receptor dimerization
Drugs 1
  • Sorafenib
  • Sunitinib
  • 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea
  • Cediranib
  • Vatalanib
  • XL999
  • TG-100801
  • XL820
  • CYC116
  • Ramucirumab
  • Pegdinetanib
  • RAF-265
  • Linifanib
  • IMC-1C11
  • Semaxanib
  • Pazopanib
  • Midostaurin
  • Axitinib
  • 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide
  • N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide
  • N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide
  • 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide
  • N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE
  • N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE
  • 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one
  • 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one
  • N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide
  • N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
  • N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
  • Cabozantinib
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Tivozanib
  • Fostamatinib
  • Erdafitinib
  • Foretinib
  • Ripretinib
  • Pralsetinib
  • Olinvacimab
Drugs 2
Diseases 1
Diseases 2
  • Gastric cancer
Novel
Name 1
SMAD family member 4
Name2
nucleoporin 214
Pathway 1
  • Signaling by NODAL
  • Signaling by NODAL
  • Signaling by Activin
  • Signaling by Activin
  • Signaling by BMP
  • TGF-beta receptor signaling activates SMADs
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • SMAD4 MH2 Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Transcriptional regulation of pluripotent stem cells
  • Ub-specific processing proteases
  • RUNX2 regulates bone development
  • RUNX3 regulates CDKN1A transcription
  • RUNX3 regulates BCL2L11 (BIM) transcription
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of cell cycle genes
  • FOXO-mediated transcription of cell cycle genes
  • Cardiogenesis
  • SARS-CoV-1 targets host intracellular signalling and regulatory pathways
  • Germ layer formation at gastrulation
  • Formation of definitive endoderm
  • Formation of definitive endoderm
  • TGFBR3 expression
  • Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
Pathway 2
  • ISG15 antiviral mechanism
  • Transport of the SLBP independent Mature mRNA
  • Transport of the SLBP Dependant Mature mRNA
  • Transport of Mature mRNA Derived from an Intronless Transcript
  • Transport of Mature mRNA derived from an Intron-Containing Transcript
  • Rev-mediated nuclear export of HIV RNA
  • Transport of Ribonucleoproteins into the Host Nucleus
  • NS1 Mediated Effects on Host Pathways
  • Viral Messenger RNA Synthesis
  • NEP/NS2 Interacts with the Cellular Export Machinery
  • Regulation of Glucokinase by Glucokinase Regulatory Protein
  • Nuclear import of Rev protein
  • Vpr-mediated nuclear import of PICs
  • IPs transport between nucleus and cytosol
  • IP3 and IP4 transport between cytosol and nucleus
  • IP6 and IP7 transport between cytosol and nucleus
  • snRNP Assembly
  • SUMOylation of DNA damage response and repair proteins
  • SUMOylation of ubiquitinylation proteins
  • Nuclear Pore Complex (NPC) Disassembly
  • Regulation of HSF1-mediated heat shock response
  • SUMOylation of SUMOylation proteins
  • HuR (ELAVL1) binds and stabilizes mRNA
  • SUMOylation of chromatin organization proteins
  • SUMOylation of RNA binding proteins
  • SUMOylation of DNA replication proteins
  • SUMOylation of DNA replication proteins
  • Transcriptional regulation by small RNAs
  • Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC)
  • tRNA processing in the nucleus
  • HCMV Early Events
  • HCMV Late Events
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
Drugs 1
Drugs 2
Diseases 1
  • Colorectal cancer
  • Juvenile polyposis syndrome
  • Hereditary hemorrhagic telangiectasia (HHT)
  • Pancreatic cancer
Diseases 2
Novel
Name 1
SMAD family member 4
Name2
notch receptor 4
Pathway 1
  • Signaling by NODAL
  • Signaling by NODAL
  • Signaling by Activin
  • Signaling by Activin
  • Signaling by BMP
  • TGF-beta receptor signaling activates SMADs
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • SMAD4 MH2 Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Transcriptional regulation of pluripotent stem cells
  • Ub-specific processing proteases
  • RUNX2 regulates bone development
  • RUNX3 regulates CDKN1A transcription
  • RUNX3 regulates BCL2L11 (BIM) transcription
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of cell cycle genes
  • FOXO-mediated transcription of cell cycle genes
  • Cardiogenesis
  • SARS-CoV-1 targets host intracellular signalling and regulatory pathways
  • Germ layer formation at gastrulation
  • Formation of definitive endoderm
  • Formation of definitive endoderm
  • TGFBR3 expression
  • Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
Pathway 2
  • Pre-NOTCH Processing in the Endoplasmic Reticulum
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Processing in Golgi
  • Pre-NOTCH Processing in Golgi
  • Notch-HLH transcription pathway
  • Defective LFNG causes SCDO3
  • NOTCH4 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • Negative regulation of NOTCH4 signaling
  • Negative regulation of NOTCH4 signaling
Drugs 1
Drugs 2
Diseases 1
  • Colorectal cancer
  • Juvenile polyposis syndrome
  • Hereditary hemorrhagic telangiectasia (HHT)
  • Pancreatic cancer
Diseases 2
Novel
Symbols
Name 1
actinin alpha 3
Name2
calcium dependent secretion activator
Pathway 1
  • Nephrin family interactions
  • Striated Muscle Contraction
Pathway 2
Drugs 1
Drugs 2
  • Calcium citrate
  • Calcium Phosphate
  • Calcium phosphate dihydrate
Diseases 1
Diseases 2

Page 16 out of 31 pages

© Madhavi K. Ganapathiraju 2012-2025